Rituximab News
FDA Approves Two New Indications for Rituxan(R) (Rituximab) in Patients With Non-Hodgkin's Lymphoma
Rituxan Improves Progression-Free Survival When Used in Combination with CVP Chemotherapy as a First-Line Treatment in Patients with Follicular Non-Hodgkin's Lymphoma.
Rheumatoid Arthritis
This study will evaluate the effectiveness of retreatment with rituximab in people with active rheumatoid arthritis (RA) who are receiving methotrexate (MTX) and who have had an inadequate response to tumor necrosis factor (TNF)...
Biogen Idec Reports Second Quarter 2006 Results
Cambridge, Mass., Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology company with leading products and capabilities in oncology, neurology and immunology, today reported its second quarter 2006 results.
Genta Receives Special Protocol Assessment from FDA for Confirmatory Trial of Genasense(R) Plus Chemotherapy in Chronic Lymphocytic Leukemia
Randomized Trial to Evaluate Fludarabine and Rituximab with or without Genasense in Previously Untreated Patients
Thousands to Benefit from Launch of Novel Rheumatoid Arthritis Therapy
Current Treatments Failing Nearly 30% of Patients with Severe RA : MabMabTheraŽ(rituximab) Offers New Hope